ArticleDiabetology & metabolic syndrome2025
Association between advanced glycation end products and estimated glomerular filtration rate: a cross-sectional analysis.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a significant public health concern associated with high morbidity and mortality rates, particularly in populations with type 2 diabetes and hypertension. Advanced glycation end products (AGEs) are implicated in CKD pathogenesis, but their association with the estimated glomerular filtration rate (eGFR) remains unclear. We aimed to assess the associations between AGE levels and the eGFR.
methodsWe conducted a cross-sectional analysis of baseline data from the Health Workers Cohort Study (2004-2006), which included 1,621 adults. AGE levels were categorized into quartiles, and the eGFR was calculated via the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2009 equation. Quantile and logistic regression models were used to assess the associations between AGEs and the eGFR, adjusting for potential confounders.
resultsThe median AGE level was 334 µU/ml, and the prevalence of low eGFR (< 60 mL/min/1.73 m²) was 4.7%. Quantile regression analysis revealed a significant reduction in the eGFR, particularly in the 10th percentile. Logistic regression models revealed that a 100 µU/ml increase in AGE level was associated with increased odds of a low eGFR (OR: 1.06, 95% CI: 1.03-1.09). Participants with very high AGE levels had greater odds of having a low eGFR than those in the lowest category did (OR: 2.21, 95% CI: 1.00-4.88).
conclusionElevated AGE levels were associated with lower eGFRs and increased odds of low eGFRs. These findings underscore the potential role of AGEs in CKD development and suggest the importance of targeting AGE accumulation for CKD prevention and management in high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.